Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04974398 · ClinicalTrials.gov registry record · Phase 3

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

A Phase 3 study of Nasopharyngeal Carcinoma, sponsored by Akeso.

Active
Registry status
Phase 3
Development phase
296
Enrollment target
20
Study locations

NCT04974398: Active Phase 3 study of Nasopharyngeal Carcinoma, sponsored by Akeso.

NCT04974398 is a Phase 3 study of Nasopharyngeal Carcinoma that is active but no longer recruiting, run by Akeso. The registered enrollment target is 296 participants, above the 58-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (410% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04974398, a Phase 3 study of Nasopharyngeal Carcinoma, is active but no longer recruiting, sponsored by Akeso.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
296 participants
Enrollment target
20
Study locations

Study Summary

This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Primary Outcome

PFS assessed by BIRC based on RECIST v1.1 .

Conditions Studied

Interventions

  • DRUG placebo
  • DRUG Penpulimab

Study Locations (20)

REG1

  • Hospital de Câncer de Barretos - Fundação Pio XII - Barretos
  • Grupo Oncoclínicas - Botafogo
  • Hospital Bruno Born - Lajeado
  • Hospital Nossa Senhora da Conceicao - Porto Alegre
  • Centro de Estudos e Pesquisa de Hematologia - Santo André
  • Instituto do Câncer do Estado de São Paulo (ICESP) - São Paulo
  • Centro de Câncer A. C. Camargo - São Paulo

New South Wales

  • Chris O'Brien Lifehouse - Camperdown
  • St Vincent's Public Hospital Sydney - Darlinghurst
  • Genesis Care North Shore - St Leonards

New York

  • Icahn School of Medicine at Mount Sinai - New York
  • Memorial Sloan Kettering Cancer Center - New York

California

  • City of Hope - Duarte

Georgia

  • Winship Cancer Institute/Emory University - Atlanta

Michigan

  • University of Michigan - Ann Arbor

Victoria

  • Sir Charles Gardner - Heidelberg

Western Australia

  • Austin Health - Nedlands

Trial Details

FieldValue
Enrollment Target 296 participants
Start Date 2021-08-16
Est. Completion 2026-12-23
Phase Phase 3
Akeso

4 total trials

What the registry record for NCT04974398 still lists

NCT04974398 is an interventional study that assigns participants to a tested intervention. The registered 296 participants enrollment target is mid-sized for trials with a published cap, above the 58-participant average among 7 other Nasopharyngeal Carcinoma trials with a reported enrollment target (410% higher).

The record links to 1 condition, with Nasopharyngeal Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT04974398 names 20 study sites across 11 states, led by REG1, New South Wales, New York.

Frequently Asked Questions

What is clinical trial NCT04974398 about?

NCT04974398 is a clinical study titled "A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma". This study is a randomized, double-blind, multi-center phase III clinical study to compare the efficacy and safety of penpulimab combined with chemotherapy and placebo combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

What is the current status of trial NCT04974398?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 296 participants. The study started on 2021-08-16. Estimated completion is 2026-12-23.

What conditions does trial NCT04974398 study?

This clinical trial studies the following conditions: Nasopharyngeal Carcinoma.

What interventions are being tested in trial NCT04974398?

The interventions under investigation include: placebo (DRUG), Penpulimab (DRUG).

Who is sponsoring clinical trial NCT04974398?

This trial is sponsored by Akeso, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04974398 being conducted?

This trial has 20 study locations across California, Georgia, Michigan, New York, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Nasopharyngeal Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05563792 · 296 participants · NA

    Options for Pain Management Using Nonpharmacological Strategies

  • NCT06828445 · 296 participants · Phase 1

    Increasing Affordable Fruits and Vegetables for Families With Food Insecurity

  • NCT06920563 · 296 participants · NA

    Remote Postpartum Blood Pressure Monitoring and Cardiovascular Education

  • NCT06309160 · 297 participants · NA

    COMPASS Across Settings (CAST) for Improving Transition Outcomes for Students With ASD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04974398, the US trial registry maintained by the National Library of Medicine. NCT04974398 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.